Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Ravindran, Menon, D; Hammerlindl, H; Gimenez, G; Hammerlindl, S; Zuegner, E; Torrano, J; Bordag, N; Emran, AA; Giam, M; Denil, S; Pavelka, N; Tan, AC; Sturm, RA; Haass, NK; Rancati, G; Herlyn, M; Magnes, C; Eccles, MR; Fujita, M; Schaider, H.
H3K4me3 remodeling induced acquired resistance through O-GlcNAc transferase.
Drug Resist Updat. 2023; 71: 100993
Doi: 10.1016/j.drup.2023.100993
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
-
Ravindran Menon Dinoop
-
Schaider Helmut
- Co-Autor*innen der Med Uni Graz
-
Bordag Natalie
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- AIMS: Drivers of the drug tolerant proliferative persister (DTPP) state have not been well investigated. Histone H3 lysine-4 trimethylation (H3K4me3), an active histone mark, might enable slow cycling drug tolerant persisters (DTP) to regain proliferative capacity. This study aimed to determine H3K4me3 transcriptionally active sites identifying a key regulator of DTPPs. METHODS: Deploying a model of adaptive cancer drug tolerance, H3K4me3 ChIP-Seq data of DTPPs guided identification of top transcription factor binding motifs. These suggested involvement of O-linked N-acetylglucosamine transferase (OGT), which was confirmed by metabolomics analysis and biochemical assays. OGT impact on DTPPs and adaptive resistance was explored in vitro and in vivo. RESULTS: H3K4me3 remodeling was widespread in CPG island regions and DNA binding motifs associated with O-GlcNAc marked chromatin. Accordingly, we observed an upregulation of OGT, O-GlcNAc and its binding partner TET1 in chronically treated cancer cells. Inhibition of OGT led to loss of H3K4me3 and downregulation of genes contributing to drug resistance. Genetic ablation of OGT prevented acquired drug resistance in in vivo models. Upstream of OGT, we identified AMPK as an actionable target. AMPK activation by acetyl salicylic acid downregulated OGT with similar effects on delaying acquired resistance. CONCLUSION: Our findings uncover a fundamental mechanism of adaptive drug resistance that governs cancer cell reprogramming towards acquired drug resistance, a process that can be exploited to improve response duration and patient outcomes.
- Find related publications in this database (using NLM MeSH Indexing)
-
Humans - administration & dosage
-
Histones - genetics
-
AMP-Activated Protein Kinases - administration & dosage
-
Down-Regulation - administration & dosage
-
Mixed Function Oxygenases - administration & dosage
-
Proto-Oncogene Proteins - administration & dosage
- Find related publications in this database (Keywords)
-
Cellular reprogramming
-
Epigenetics
-
Metabolism
-
OGT
-
TET1
-
Cancer persisters
-
Adaptive cancer drug resistance
-
Acquired drug resistance